In an adult newly diagnosed with HIV, what is the recommended antiretroviral therapy regimen and CD4‑based prophylaxis for opportunistic infections?

CD4 Count and Antiretroviral Treatment in Newly Diagnosed HIV

Immediate ART Initiation Regardless of CD4 Count

Start antiretroviral therapy on the day of HIV diagnosis—or within 7 days—for all adults with detectable HIV RNA, regardless of CD4 count, viral load, age, or clinical status. This approach reduces all-cause mortality by 44–57% and markedly lowers progression to AIDS, tuberculosis, and other opportunistic infections. 1

• Do not postpone ART while awaiting routine laboratory results; the only exception is HLA-B*5701 testing when an abacavir-containing regimen is planned. 1
• Eliminate structural barriers (staffing shortages, insurance delays, drug-stock gaps) that prevent same-day ART initiation at the first clinic visit. 1

Baseline Laboratory Testing

Draw the following tests before starting ART, but do not delay treatment while awaiting results:

• HIV-1 RNA viral load 1
• CD4 cell count 1
• Genotypic resistance testing (reverse transcriptase, protease, integrase) 1
• HLA-B*5701 allele testing (mandatory before any abacavir use) 1
• Hepatitis B and C serologies 1
• Complete blood count and comprehensive metabolic panel 1
• Fasting lipid profile and glucose 1
• Urinalysis for protein and glucose 1

Preferred First-Line ART Regimens

Primary Recommendation

Bictegravir/tenofovir alafenamide (TAF)/emtricitabine (single tablet, once daily) is the preferred regimen because it provides the highest efficacy, best tolerability, strongest resistance barrier, minimal drug-drug interactions, and does not require HLA-B*5701 testing, enabling same-day start. 1

Equally Effective Alternatives

• Dolutegravir + TAF/emtricitabine (once daily) offers comparable efficacy with extensive long-term safety data and superior renal and bone safety versus tenofovir disoproxil fumarate (TDF). 1
• Dolutegravir/abacavir/lamivudine (once daily) may be used only after confirming a negative HLA-B*5701 result and should be avoided in patients with significant cardiovascular risk; a tenofovir-based regimen is preferred in such cases. 1

When Integrase Inhibitors Cannot Be Used

• Darunavir/ritonavir (or cobicistat) + TAF/emtricitabine for patients with suspected or confirmed integrase inhibitor resistance. 1
• Efavirenz + TDF/emtricitabine should be reserved for patients with active tuberculosis co-infection because of its neuropsychiatric adverse-effect profile and increased suicidality risk. 1

Regimens to Avoid for Rapid Start

• Do not use NNRTI-based regimens or abacavir-containing regimens for same-day initiation because they require baseline resistance testing and HLA-B*5701 results, which delay therapy. 1
• Rilpivirine-based regimens are contraindicated when baseline HIV-1 RNA > 100,000 copies/mL or CD4 < 200 cells/µL because of markedly increased virologic failure risk. 1

CD4-Based Opportunistic Infection Prophylaxis

Pneumocystis Pneumonia (PCP)

• Initiate trimethoprim-sulfamethoxazole (double-strength, one tablet three times weekly) for all patients with CD4 < 200 cells/µL. 1
• Continue prophylaxis until CD4 rises above 200 cells/µL for at least 3 consecutive months. 1

Mycobacterium Avium Complex (MAC)

• Primary MAC prophylaxis is no longer recommended when effective ART is started promptly, as early treatment markedly lowers MAC incidence. 1

Cryptococcal Disease

• Prophylaxis is not recommended in high-resource settings with low disease prevalence. 1

ART Timing with Active Opportunistic Infections

Tuberculosis Co-infection

CD4 Count	TB Form	ART Initiation Timing	Rationale
< 50 cells/µL	Non-meningeal TB	Within 2 weeks of TB therapy start	Reduces mortality in severely immunocompromised patients [1]
≥ 50 cells/µL	Non-meningeal TB	Within 2–8 weeks of TB therapy start	Balances efficacy with risk of IRIS [1]
Any	TB meningitis	Within 2 weeks (expert consensus)	Close monitoring for IRIS is essential [1]

ART regimens compatible with rifampin-based TB therapy:

• Dolutegravir 50 mg twice daily, or 1
• Efavirenz 600 mg once daily, or 1
• Raltegravir 800 mg twice daily 1
• Each combined with two NRTIs 1

Bictegravir must not be co-administered with rifampin due to a clinically significant drug-drug interaction. 1

Cryptococcal Meningitis

• Delay ART for 4–6 weeks after initiating antifungal therapy to minimize the risk of severe immune reconstitution inflammatory syndrome (IRIS). 1
• Start ART at 2 weeks only if the patient shows clinical improvement, controlled intracranial pressure, negative CSF cultures, and can be closely monitored. 1

Other Opportunistic Infections

• For most other OIs (e.g., Pneumocystis pneumonia, bacterial infections), initiate ART within 2 weeks of starting infection-specific therapy. 1

Malignancy

• Start ART immediately upon cancer diagnosis, with careful review of potential drug-drug interactions. 1

Special Populations

Pregnancy

• Preferred regimen: Dolutegravir + TAF/emtricitabine 1
• If a protease inhibitor is required, use darunavir 600 mg + ritonavir 100 mg twice daily (once-daily dosing is insufficient in pregnancy). 1

Renal or Bone Disease

• Avoid TDF in patients with estimated creatinine clearance < 60 mL/min or with osteopenia/osteoporosis; use TAF instead to reduce nephrotoxicity and bone loss. 1

Hepatitis B Co-infection

• Start an ART regimen that includes TDF or TAF together with lamivudine or emtricitabine to provide dual activity against HBV. 1
• Entecavir may be added for HBV treatment but should be avoided if HIV-RNA is not suppressed, as it can select for HIV drug resistance. 2

Post-Initiation Monitoring

• HIV-1 RNA viral load: Check at 4–6 weeks after starting ART, then every 4–6 weeks until undetectable (< 50 copies/mL). 1
• CD4 count: Measure every 3–6 months during the first year, then at longer intervals as immune recovery stabilizes. 1
• Monitor eGFR, urinalysis, glycosuria, and proteinuria at ART initiation, after any regimen change, and every 6 months once HIV-RNA is stable. 2

Common Pitfalls to Avoid

• Never delay ART while awaiting complete laboratory results (except HLA-B*5701 for abacavir); postponement eliminates the survival benefit of early treatment. 1
• Never prescribe abacavir without confirming a negative HLA-B*5701 result to prevent potentially fatal hypersensitivity reactions. 1
• Do not prescribe TDF to patients with low creatinine clearance or osteoporosis; substitute TAF to avoid avoidable nephrotoxicity and bone loss. 1
• In cryptococcal meningitis, do not start ART early unless strict clinical criteria are met (clinical improvement, controlled intracranial pressure, negative CSF cultures), as early initiation raises the risk of severe IRIS. 1
• In patients with CD4 < 50 cells/µL and TB, delaying ART beyond 2 weeks markedly increases mortality; start promptly as outlined above. 1